EUCTR2019-001075-36-DE进行中（未招募）1 期
A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD - - CaboCHILD
niversitätsmedizin Mainz0 个研究点目标入组 20 人开始时间: 2020年2月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent
- •3. Histological/cytological or non-invasive (according to EASL/AASLD guidelines) diagnosis of HCC
- •4. Availability of a recent (up to 28 days old) CT/MRI images of thorax and abdomen
- •5. Subject’s HCC is not amenable to a curative treatment approach (e.g., transplant, surgery, radiofrequency ablation) corresponding to BCLC
- •classification B/C.
- •6. Progression or toxicities following one prior systemic therapy for HCC
- •7. Recovery to = grade 1 from toxicities related to any prior treatments, unless the adverse events are clinically non-significant and/or stable on
- •supportive therapy
- •8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •9. Adequate hematologic function, based upon meeting the following laboratory criteria within 7 days before enrollment:
- •absolute neutrophil count (ANC) = 1200/mm3 (= 1.2 x 109/L)
- •platelets = 60,000/mm3 (= 60 x 109/L)
- •hemoglobin = 8 g/dL (= 80 g/L)
- •10. Adequate renal function, based upon meeting the following laboratory criteria within 7 days before enrollment: serum creatinine = 1.5 × upper limit of normal or calculated creatinine clearance = 40 mL/min (using the Cockcroft-Gault equation)
- •11. Liver function Child-Pugh (CP) score B7-8
- •12. ALBI (albumin-bilirubin) grade 1-2
- •13. Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) < 7.0 × upper limit of normal (ULN) within 7 days before enrollment
- •14. Antiviral therapy per local standard of care if active hepatitis B (HBV) infection
- •15. Capability to understand and comply with the protocol requirements (e.g. sufficient knowledge of German language to answer the questionnaires ability to swallow intact tablets).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 5
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma
- •2. Receipt of more than 1 prior systemic therapy for advanced HCC. Additional prior systemic therapies used as adjuvant or local therapy are allowed.
- •3. Any type of anti-cancer agent (including investigational) within 2 weeks before enrollment
- •4. Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment (e.g., I-131 or Y-90) within 6 weeks of enrollment. Subject cannot be enrolled if there are any clinically relevant ongoing complications from prior radiation therapy.
- •5. Prior Cabozantinib treatment
- •6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months before enrollment. Eligible subjects must be without corticosteroid treatment at the time of enrollment.
- •7. Concomitant anticoagulation, at therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, low molecular weight Heparin (LMWH), thrombin or activated coagulation factor X (FXa) inhibitors, or antiplatelet agents (e.g., clopidogrel). Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (= 1 mg/day), and low-dose LMWH are permitted.
- •8. The subject has uncontrolled, significant intercurrent or recent illness.
- •9. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding are excluded with the following clarification: subjects with history of prior variceal bleeding must have been treated with adequate endoscopic therapy without any evidence of recurrent bleeding for at least 6 months prior to study entry and must be stable on optimal medical management (e.g. non-selective beta blocker, proton pump inhibitor) at study entry.
- •10. Women who are pregnant, nursing, or who plan to become pregnant while in the Trial.
- •11. Women of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at informed consent, for the duration of study participation and for at least 4 months after last dose of the study drug. Because oral contraceptives might possibly not be considered as effective Methods of contraception during the Treatment with cabozantinib, they should be used together with another method, such as a barrier method.
- •12. Currently receiving any other investigational agent or received an investigational agent within 30 days (or within 5 times the half-life of this agent or its relevant Metabolits, the longer period apply) before the first dose of Cabozantinib.
- •13. Hepatic encephalopathy Grad I-IV according to CP classification (= 2 points) and West Haven Criteria.
- •14. Moderate or severe ascites according to CP classification (= 3 points).
- •15. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms within 7 days before enrollment.
研究者
相似试验
进行中（未招募）
1 期
Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence before radical prostatectomypatients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes.MedDRA version: 20.0Level: LLTClassification code 10007113Term: Cancer of prostateSystem Organ Class: 100000004864EUCTR2019-001920-36-FRCHU de NIMES12
进行中（未招募）
1 期
A Phase IIa study to assess the safety, tolerability, plasma pharmacokinetics and efficacy of intermittent oral administration of standard levodopa/carbidopa vs. semi-continuous intra-oral administration of levodopa/carbidopa in patients with advanced Parkinson’s disease who suffer motor fluctuations.Parkinson's disease patients who suffer motor fluctuations willparticipate in the studyMedDRA version: 17.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-002295-87-ITSynAgile Corporation18
进行中（未招募）
2 期
A clinical trial to study the effects of two drugs, Folfox and CT-011 in patients with cancer of large intestine.CTRI/2014/08/004922CureTech Ltd171
进行中（未招募）
1 期
Study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastaticmelanomaEUCTR2011-004501-24-GBCureTech Ltd.100
进行中（未招募）
不适用
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) - Women with Breast Cancer and Established Metastatic Bone DiseaseMetastaic Bone Disease (MBD)MedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-002669-38-DKMerck & Co., Inc.